Grace Therapeutics (GRCE) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Grace Therapeutics (GRCE) has outperformed Stablecoin Development (SDEV) over the past year, losing 46.4% versus a loss of 88.4%. Over five years, GRCE leads with a -79.3% price change compared with -100.0% for SDEV. Stablecoin Development is the larger company by market cap ($36.9 million vs $36.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRCE | SDEV |
|---|---|---|
| Share price | $1.71 | $0.50 |
| Market cap | $35.97M | $36.90M |
| 1-day change | -0.58% | -10.30% |
| YTD return | -50.58% | -98.23% |
| 1-year return | -46.39% | -88.37% |
| 5-year return | -79.35% | -99.98% |
| P/E ratio (TTM) | — | 0.19 |
| EPS (TTM) | $-1.16 | $2.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-7.79M | $-630.78M |
| 52-week high | $5.18 | $99.75 |
| 52-week low | $1.64 | $0.467 |
| Distance from 52-week high | -66.99% | -99.50% |
| Analyst consensus | none | — |
| Avg. price target upside | +243.27% | — |
| Average volume | 119.27K | 16.98M |
| Shares outstanding | 21.04M | 73.80M |
| Employees | 5 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRCE has outperformed SDEV by 42.0 percentage points over the past year.
About Grace Therapeutics
GRCE stock →Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
GRCE vs SDEV FAQ
Which is bigger, Grace Therapeutics or Stablecoin Development?
Stablecoin Development (SDEV) is larger, with a market capitalization of $36.90M compared with $35.97M for Grace Therapeutics (GRCE).
Which stock has performed better over the past year, GRCE or SDEV?
GRCE returned -46.39% over the past 12 months, compared with -88.37% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Grace Therapeutics and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.